Page 50 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors

Chapter 3
Table 1: Included studies
Author, ref
Andreasen1 Valstar2 Niparko3 Dawson4 Myssiorek5 Renehan6
Fee7 Chen8
Jackson9 Phillips10 Yugueros11
Leverstein12 Wittekindt13 Laskawi14 Glas15 Samson16
Makeieff17
Maxwell18 Makeieff19 Zbaren20
Redaelli deZinis21
Carew22 Suh23
Nohr24
Malard25
Leonetti26
AbuGhanem27 Liu28
Period
1985-2010 1992-2012 1935-1975 1950-1971 1950-1983 1952-1992
1955-1973 1960-2004
1962-1992 1965-1985 1965-1993
1974-1995 1974-2004 1975-1991 1976-1992 1979-1988
1981-2003
1982-1997 1982-2008 1983-2001
1983-2004
1984-1993 1984-2004 1985-2012 1988-2008 1989-2002 1991-2013 2004-2012
RPA Cohort selection criteria
151 PA, 1st, 2nd RPA, PAR
125 PA, 1st, 2nd RPA, all SG*
48 1st + later RPAs, PAR
31 1st and later RPAs
27 unclear
114 1st RPA, PAR, excl. residual tumor/ spill
26 unclear, PAR, excl. <3mo
34 1st + later RPA, excl. CEPA / insuff follow-up
38 1st and later RPAs 126 1st + later RPAs
39 1st + later RPAs, PAR
29 1st + later RPAs, PAR
108 1st + later RPAs
94 1st + later RPAs
52 1st + later RPA, PAR, excl<6mo
21 Unclear RPA; all subtot. excision + RT
32 unclear, PAR, excl. FND / RT / MT
35 1st RPA, no prior RT 62 1st + later RPAs
33 1st RPA, PAR, excl.
residual tumor 33 1st + later RPAs
31 1st and later RPAs
20 1st RPA, incl. MT, PAR
198 1st + later RPAs and FND 32 1st + later RPA, intra-PAR 42 1st + later RPAs, PAR
22 1st + later RPAs, PAR
58 unclear, excl.FND, MT, RT
Study aim
Incidence, rec. rate, MT Incidence, rec. rate, MT Analysis of treated cases Role of RT in RPA
Rec. patterns, causes, treatment Treatment, outcome
Results of surgical therapy Role of RT in RPA
Treatment results
Tumor behavior+ outcome
Limited resection + RT vs parotidectomy
Treatment results
Histopath., risk factors RPA
Treatment, outcome
Treatment, outcome
Outcome FN preservation + RT
FN palsy, recovery with/ without monitoring
Treatment results Outcome, riskfactors RPA
Effect initial treatment, outcome
Management and progn. factors
Control rate and role of RT Charact. RPA, risk fact. MT Distribution + sympt. in FND Results, progn. factors Diagnosis, treatment, result Treatment, outcome
Benefit intraop. FN monitor
48
PA=pleomorphic adenoma; RPA=recurrent pleomorphic adenoma; PAR=parotid; SG=salivary glands; RT=radiotherapy; FND=facial nerve dysfunction; CEPA=carcinoma ex pleomorphic adenoma; MT=malignant transformation
Initial presentation
The national data sets provided a crude and European Standardized Rate for primary PA of 4-5/100,000/year [1,2]. The crude 1st RPA rate depended on follow- up time. Although contemporary series reported this to be <2%, it increased from 2% at 5 years to 7% at 20 years in data not corrected for death as a competing event